Breast conservation surgery versus total mastectomy among women with localized breast cancer in Soweto, South Africa by Cubasch, Herbert et al.
RESEARCH ARTICLE
Breast conservation surgery versus total
mastectomy among women with localized
breast cancer in Soweto, South Africa
Herbert Cubasch1,2,3☯, Maureen Joffe2,3,4☯, Paul Ruff3,5,6☯, Donald Dietz7‡,
Evan Rosenbaum7‡, Nivashni Murugan1,2‡, Ming Tsai Chih1,2‡, Oluwatosin Ayeni2,3‡,
Caroline Dickens6‡, Katherine Crew7,8,9‡, Judith S. Jacobson8,9☯, Alfred Neugut7,8,9☯*
1 Department of Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South
Africa, 2 Batho Pele Breast Unit, Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa,
3 Wits Health Consortium, Johannesburg, South Africa, 4 Department of Paediatrics, Faculty of Health
Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5 Division of Medical Oncology,
Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
South Africa, 6 Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand,
Johannesburg, South Africa, 7 Department of Medicine, College of Physicians and Surgeons, Columbia
University, New York, New York, United States of America, 8 Herbert Irving Comprehensive Cancer Center,
College of Physicians and Surgeons, Columbia University, New York, New York, United States of America,
9 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York,
United States of America
☯ These authors contributed equally to this work.




Breast conserving surgery (BCS) has become the preferred surgical option for the manage-
ment of patients with nonmetastatic breast cancer in high-income countries. However, little
is known about the distribution and determinants of BCS in low-and middle-income coun-
tries, especially those with high HIV prevalence.
Methods
We compared demographic and clinical characteristics of female patients who received
BCS and those who received total mastectomy (TM) for nonmetastatic invasive carcinoma
of the breast in Soweto, South Africa, 2009–2011. We also developed a multivariable logis-
tic regression model of predictors of type of surgery.
Results
Of 445 patients, 354 (80%) underwent TM and 91 (20%) BCS. Of 373 patients screened for
HIV, 59 (15.8%) tested positive. Eighty-two of 294 patients with stage I/II disease (28%), but
just 9 of 151 (6%) with stage III disease had BCS (p<0.001). All women who received BCS
(except for seven who received completion mastectomy within 6 weeks of BCS) and 235
(66.4%) women who received TM were referred for radiation therapy (RT). In our multivari-
able analysis, age group 50–59 years (OR = 2.28, 95% CI = 1.1–4.8) and70 years (OR =
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9.55, 95% CI = 2.9–31.2) vs. age group <40 years, stage at diagnosis (stage II (OR = 3.79,
95% CI = 1.6–8.2) and stage III (OR = 27.8, 95% CI = 9.0–78.8) vs. stage 1, HIV (HIV posi-
tive (OR = 3.19, 95% CI = 1.3–7.9) vs. HIV negative) and HER2-enriched subtype (OR =
3.50, 95% CI = 1.2–10.1) vs. triple negative were independently associated with TM.
Conclusion
TM was more common than BCS among patients with nonmetastatic breast cancer in
Soweto, not only among patients with locally advanced disease at diagnosis, but also
among women with stage I and II disease.
Introduction
Breast cancer is the most common cancer affecting women. According to GLOBOCAN, 1.6
million women are diagnosed with the disease worldwide, each year, and 521,000 die with it
[1]. High-income countries (HICs)have higher incidence rates of breast cancer than low- and
middle-income countries (LMICs), such as those in sub-Saharan Africa, but better survival.
Sub-populations within countries also differ in incidence and mortality[2, 3]. The poor out-
comes observed in low-income populations may reflect advanced stage at presentation, as well
as inconsistent adherence and lack of access to state-of-the-art treatment. In addition, comor-
bidities, such as HIV/AIDS, may make disease progression more rapid and treatment more
complex.
The overall prevalence of HIV infection in South Africa is estimated at 19.2%[4]. A national
program to provide anti-retroviral therapy (ART) for the treatment of HIV/AIDS was
launched in 2004, leading to significant improvement in life expectancy[5]. Meanwhile, the
incidence of cancers common in HICs, including breast cancer, has risen. South Africa’s
pathology based National Cancer Registry reports that breast cancer incidence rose from 5280
cases in 2000, accounting for 18.8% of cancers in women, to 7086 cases in 2011, accounting for
21.5% of cancers [6, 7].
Landmark studies by Veronesi et al (1981)[8] and by Fisher et al. (1985) [9] demonstrated
that patients who received breast conserving surgery (BCS) and radiation therapy (RT) did not
differ in overall survival from those who received total mastectomy (TM) for the treatment of
localized invasive breast cancer (although they had higher rates of local recurrence).[9] There-
after, BCS followed by RT came into routine use and became a preferred option. Data accrued
between 1985 and 2002 continued to show equivalent overall survival rates for patients under-
going TM and those receiving BCS plus RT.[10, 11]. Meanwhile, TM came to be combined
with primary or secondary breast reconstruction options; innovative oncoplastic breast recon-
structive procedures[12] were found to improve cosmetic outcomes over those of the original
quadrantectomy or lumpectomy procedures while maintaining oncological safety.
A review of Surveillance, Epidemiology, and End Results (SEER 2010) data from the United
States showed that 95.4% of patients undergoing BCS also received adjuvant RT; RT receipt
was associated with surgery type, age, comorbidities, income, patient desire to avoid RT, and
level of surgeon involvement in the decision.[13] It was also associated with insurance cover-
age.[14]
Patients with breast cancer present with more advanced disease in South Africa than in the
United States. Reasons may be poorer patient awareness, lack of population screening pro-
grams, cultural barriers, and poor access to a sometimes dysfunctional health care system[15].
Breast cancer surgery in Soweto, South Africa
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Fears of mutilation and poor treatment outcomes may also delay diagnosis. Although intro-
ducing BCS as an option and discussing its pros and cons with patients is challenging and adds
complexity to an already stressed health system, we believe it is necessary to address our
patients’ fears and expectations.
South Africa has a high prevalence of HIV, but most patients with HIV have access to ART
[4]. The choice of surgical procedures at our institution, Chris Hani Baragwanath Academic
Hospital (CHBAH) in Soweto, South Africa, is usually not influenced by the HIV status of our
patients, although we prefer TM for weak and cachectic patients who are candidates for surgery.
We previously analyzed HIV status and breast cancer presentation among patients diag-
nosed at CHBAH. Our results indicated that the prevalence of HIV among breast cancer
patients was similar to that among women in the general population, and that breast tumor
characteristics were not associated with HIV status.[16] We now have investigated variations
in surgical practice and their possible associations with clinical and demographic factors
(including HIV status) among breast cancer patients at CHBAH. In addition, we assessed early
reoperations in the context of recently changed international margin guidelines.
Methods
Setting and patients
CHBAH is the largest tertiary care hospital in South Africa. It is located in Soweto, south-west
of Johannesburg, and primarily serves the 3 million black and low-income residents of Soweto
and its surrounding neighborhoods. Patients who present with a breast lesion at CHBAH
undergo triple assessment (clinical examination, imaging and histopathology), and those diag-
nosed with breast cancer receive their surgery and follow-up care at CHBAH. However, for
chemo- and radiation therapy, patients must travel to Charlotte Maxeke Academic Hospital
(CMJAH), 18 kilometers from CHBAH.
At CHBAH, the physical retrieval of patient records is often problematic and time-consum-
ing for clinicians. Therefore, in 2006 the Surgical Breast Unit established its own electronic
database of patient information in. In 2008, the unit was registered with the International
Breast Centres Network and developed a standardized approach to breast cancer diagnosis,
treatment and follow up, coordinated via a weekly multidisciplinary oncology meeting
attended by cancer surgeons, medical and radiation oncologists, and palliative care
practitioners.
For this study, we reviewed the records of all the female patients in the database who were
newly diagnosed with invasive carcinoma of the breast from January 1, 2009 through Decem-
ber 31, 2011.[17] The study was approved by the Wits Human Research Ethics Committee
(Medical).
We excluded from our analysis 46 patients who had stage IV (metastatic) disease at diagno-
sis and 110 patients who did not undergo surgery for other reasons (patients with nonresect-
able cancers, including those who could not be down-staged with systemic treatment and
those who defaulted or died during primary systemic treatment).
Surgical procedures
Surgery remains the main treatment modality for localized breast cancer. Our approach was to
consider the feasibility for BCS in discussion with each patient. We found the indication to be
a delicate balance between technical feasibility and safety, individual patient preferences, and
patients’ psychosocial and socioeconomic circumstances. Where possible, we addressed the
barrier of additional out-of-pocket patient transport costs associated with mandatory RT at
CMJAH by helping patients apply for temporary disability grants. We performed few primary
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and delayed post-mastectomy reconstructions due to resource constraints (shortage of operat-
ing theater time, inconsistent supply of breast implants, and limited availability of plastic sur-
gery services) and consequently limited patient demand. We almost always performed level 1
and level 2 oncoplastic procedures (rather than simple lumpectomies)[18]. We were therefore
able to treat relatively large lesions with predictably acceptable cosmetic outcomes, while
avoiding the morbidity associated with distant flaps.
During the period when our study patients were diagnosed and treated, it was not always
easy to deliver surgical services. CHBAH frequently faced logistic challenges, shortages of
linen, electricity, water and consumable supplies (e.g., drains, sutures, medicines). In 2009,
mammography services were locally unavailable for a month due to machine breakdown, and
in 2010, some of our health workers participated in a prolonged public sector strike that
brought service delivery to a near standstill and subjected non-striking staff to threats of vio-
lence. Despite these problems, most patients who required surgery were operated on within
two weeks of a confirmed diagnosis.
Many of our patients were morbidly obese, and many had very large breasts [19]. When
such patients required TM, they were routinely offered contralateral reduction mastopexy.
Oncoplastic procedures, particularly bilateral breast reductions, were appreciated by patients,
facilitated homogeneity, and enhanced the effectiveness of RT[20].
In the choice of procedure, we considered the quadrant of the lesion and the size of the
breast, and we limited ourselves to a few easily reproducible and standardized oncoplastic pro-
cedures. For inner and outer upper quadrant lesions, we used segmentectomies with parenchy-
mal flaps [12]. Lower inner and outer quadrant lesions were preferably addressed with
modified Wise reduction patterns[21]. For large-breasted patients, the preferred option was
oncoplastic bilateral reduction using the Wise pattern. Because we used a two-team approach
(one team operating on the right breast and the other on the left, simultaneously), these proce-
dures took no more time than routine mastectomies. This approach also enabled senior sur-
geons to supervise junior staff closely, to reinforce training and team building.
For patients who had very large lesions that did not allow for primary skin closure (usually
following primary chemotherapy), we preferred to use thoraco-epigastric abdominal wall
advancement flaps, which lead to less morbidity than latissimus dorsi flaps as well as taking
less operating time.
We referred patients with locally advanced disease for primary systemic treatment and re-
evaluated them post-treatment for potential resectability.
During the study period, we performed sentinel lymph node dissection on patients with a
T1 or small T2 lesion and a clinical N0 axilla. In this series, due to exclusion of patients with
primary lesions greater than 4cm, irregular availability of radioactive tracers or nuclear medi-
cine services, or lymphadenopathy associated with HIV, fewer than 10% of patients had a sen-
tinel node biopsy. When the sentinel node was found to be positive or if the axilla intra-
operatively was highly suspicious, a level 1 and partial level 2 axillary node dissection was per-
formed. Intraoperative frozen sections were rarely available. Because of the high prevalence of
HIV infection in this patient population, patients were often found to have histologically can-
cer-negative reactive lymph nodes.
The average post-operative hospital stay was two days, and patients were discharged with a
closed suction drain and followed up weekly in a specialized dressing clinic.
Data and statistical analysis
Data were extracted from the patients’ electronic medical records. The variables recorded were
patient age, race, menopausal status, year of diagnosis, Manchester staging, diagnosis on
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histopathology, HIV status, histopathology grade, receptor (estrogen, progesterone, HER2)
status, tumor size, type of first surgery, recurrence status, time to recurrence, and vital status;
Ki-67 analyses were not available during this period. In addition, the records included only
limited demographic data and no data on socioeconomic status.
We compared patients who received BCS to those who received TM for early and locally
advanced breast cancers. We used chi-square tests to evaluate the statistical significance of dif-
ferences in frequency distributions of the categorical variables. We then developed multivari-
able logistic regression models of factors associated with type of surgery, based on the results
of the univariate analyses. Our initial hypothesis was that HIV status would be associated with
type of surgery. We included in the model factors that we thought might be associated with
HIV status and type of surgery (including but not limited to those with p-values <0.1) and
were not in the causal pathway, consistent with the standard definition of confounding.
Results
Of 445 women included in the study, 354 (79.6%) underwent TM and 91 (20.4%) BCS. Of 330
patients who received surgery as the first (initial) treatment modality, 246 (74.5%) received
TM and 84 (25.5%) BCS. Of 115 who received surgery following systemic treatment, 108
(93.9%) had TM and 7 (6.1%) BCS (p<0.001) (Table 1).
Nearly 40% of surgical patients were younger than 50 years of age, and more than 90% were
of black African descent. Women younger than 40 years of age were more likely to receive
BCS than those over 60 years. Of 373 surgical patients with known HIV status, 59 (15.5%)
were HIV-positive.
Seventeen of 32 patients with stage I disease (53.1%), 195 of 262 with stage II disease
(74.4%), and 142 of 151with stage III disease (94.0%) had a TM (p<0.001). Patients with lym-
phovascular invasion (p = 0.02), a feature of aggressive disease, and those with the HER2-e-
nriched intrinsic subtype (p = 0.02) appear to have been more likely to receive TM than
patients without those features.
Of the 445 surgically treated patients, 41 (9.2%) underwent re-operation within 6 weeks
after the first surgery; 38 reoperations (92.6%) were due to close or involved margins. Other
reasons were poor cosmesis, positive sentinel lymph node, or inadequate axillary lymph node
dissection (some cases involved more than one reason). Of the 41 patients, 23 (56.1%) had had
BCS and 18 (43.9%) TM (p<0.001) (Fig 1).
Of the 354 patients who underwent TM, 235 (66.4%) were referred for RT, of whom 203
(86.4%) received it. In the BCS group of 91patients, 7 had a completion mastectomy (mastec-
tomy performed after BCS because of a problem, usually close or involved margins) within 6
weeks and were not referred for RT. The remaining 84 were referred for RT of whom 66
(78.6%) received it. The referred patients who did not receive RT (32 post TM and 18 post
BCS) either defaulted, had change of treatment plan, progressed, died or had untraceable
records.
On univariate analysis at p<0.1, age (p = 0.029), stage at diagnosis (p<0.001) and lympho-
vascular invasion (p = 0.0224) were associated with type of surgical procedure. HIV, race,
tumor grade ductal vs. lobular histology and intrinsic subtype (luminal A, luminal B. HER2
positive and triple negative) were not associated.
In a multivariable logistic regression model, older age group (50–59 (p = 0.029) and70
(p<0.001) vs. age group < 40), stage at diagnosis (stage II (p = 0.002) and stage III (p<0.001)
vs. stage 1), HIV (HIV positive (p = 0.13) vs. HIV negative) and intrinsic subtype (HER2-e-
nriched subtype (p = 0.018) vs. triple negative) were independently associated with TM
(Table 2).
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Table 1. Demographic and clinical characteristics of patients who underwent surgery at CHBAH, Soweto, South Africa, 2009–2011, by type of first
surgery.
TM BCS Total
N % N % N %
Totalsa 354 79.6 91 20.4 445 100.0
Age group
18–39 55 15.5 20 22.0 75 16.9
40–49 79 22.3 22 24.2 101 22.7
50–59 100 28.2 31 34.1 131 29.4
60–69 61 17.3 13 14.2 74 16.6
70 and above 59 16.7 5 5.5 64 14.4
Race/ethnicity
Black 325 91.8 82 90.1 407 91.9
Asian 6 1.7 4 4.4 10 2.1
Mixed/Coloured 13 3.7 1 1.1 14 3.0
White 10 2.8 4 4.4 14 3.0
Stage at diagnosis
I 17 4.8 15 16.5 32 7.2
II 195 55.1 67 73.6 262 58.9
III 142 40.1 9 9.9 151 33.9
Tumor grade*
1 38 10.9 11 12.1 49 11.2
2 162 45.7 41 45.1 203 45.6
3 139 39.1 37 40.7 176 39.4
Histology**
Invasive ductal 330 93.2 88 96.7 418 93.9
Invasive lobular 16 4.5 2 2.2 18 4.0
Mixed ductal and lobular 2 0.6 1 1.1 3 0.7
Others 3 0.8 0 0.0 3 0.7
Intrinsic subtypes***
Luminal A 27 8.2 10 10.9 39 8.8
Luminal B 207 57.9 51 56.0 256 57.5
HER2 enriched 48 13.6 6 6.6 54 12.1
Triple negative 61 17.2 21 23.1 82 18.4
ER and PR expression†
ER positive alone 44 12.4 10 11.0 54 12.1
ER and PR positive 179 50.6 46 50.5 225 50.6
PR positive alone 14 4.0 6 6.6 20 4.5
ER and PR negative 116 32.8 29 31.9 145 32.6
HIV status on blood test 6 weeks after diagnosis‡
Negative 245 69.2 69 75.8 314 70.6
Positive 49 13.8 10 11.0 59 13.3
Lymphovascular invasion↨ 0
Present 145 41.0 25 27.5 170 38.2
Absent 151 42.7 48 52.7 199 44.7
Closest invasive marginsΔ
<1mm 30 8.5 13 14.3 44 9.9
1mm & <5mm 46 13.0 17 18.7 64 14.4
5mm—10mm 66 18.6 25 27.5 91 20.4
(Continued)
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Table 1. (Continued)
TM BCS Total
N % N % N %
>10mm 182 51.4 33 36.3 214 48.1
Timing of surgery
Primary (before other tx) 246 69.5 84 92.3 330 74.2
Secondary 108 30.5 7 7.7 115 25.8
Radiation therapy
Received 203 57.3 66 72.5 265 59.6
Defaulted 32 13.6 16 17.6 52 11.7
Not prescribed 119 33.6 7∏ 7.7 128 28.8
a The percentages in the Totals row are row percentages. The other percentages are column percentages.
*17 patients were missing data on tumor grade.
**3 patients were missing data on histology.
***24 patients were missing data on molecular subtype.
†14 patients were missing data on ER and 16 patients on PR expression.
‡72 patients were missing data on HIV status.
↨86 patients were missing data on lymphovascular invasion.
Δ 42 patients were missing data on closest invasive margins.
∏ Had completion mastectomy within 6 weeks
https://doi.org/10.1371/journal.pone.0182125.t001
Fig 1. Patients excluded from and included in the analysis of women with breast cancer who
underwent surgery at CHBAH, Soweto, South Africa, 2009–2011.
https://doi.org/10.1371/journal.pone.0182125.g001
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HIV status was not associated with stage but with age at diagnosis (data not shown).
Discussion
In this cohort of patients who underwent surgery for breast cancer at a public hospital in
Soweto, South Africa, we found that only ~20% received BCS. Factors associated with TM
were later stage breast cancer, older age, and HIV infection.
A recent study showed that, in the United States, among women with early stage (I or II)
breast cancer, 58% underwent BCS, 36% TM, 3% radiation or chemotherapy without surgery,
and about 2% no treatment.[22] However, among our patients in South Africa, 72% of women
with early stage breast cancer underwent TM and only 28% received BCS. In the United States,
58% of women with stage III breast cancer undergo TM because their large tumors make it dif-
ficult to achieve an acceptable oncologic or cosmetic outcome; only 14% of women diagnosed
with stage III disease receive BCS. Among our South African patients with stage III disease,
94% received TM and 6% BCS. In higher-income countries, many patients prefer BCS, and
most patients with early disease or a good response to neoadjuvant chemotherapy are consid-
ered good BCS candidates.
Doctors in our specialist CHBAH breast unit also have a preference for BCS. However, we
need to acknowledge the patient’s wishes and engage each patient individually in the surgical
decision making process. Reasons to opt for TM include absolute and relative contra-indica-
tions (e.g., inflammatory carcinomas and multi-centric tumors, late stage, and large lesions),
major socio-economic obstacles for patients (e.g., out-of-pocket transport costs to the RT cen-
ter at CMJAH for the 3 or 6 week course of regular or hypo-fractionated treatment with 5 visits
per week, or time conflict with job or family demands), patient preferences, and often the
desire of both doctors and patients to keep treatment plans as simple as possible. In our
resource-constrained health care system, numerous long queues for public transport, patient
records, consultations, and medication, and delayed lead times for treatment appointments
are major obstacles to patients’ adherence to treatment.
In our model, taking age, stage, and intrinsic subtype into account, patients with HIV were
more likely to undergo TM than those who were HIV-negative. Even if surgeons did not
Table 2. Odds ratios (OR) and 95% confidence intervals (CI) for the association of demographic and
clinical factors with receipt of TM vs BCS.
OR 95% CI p-value
Age 1.1 1.0–1.1 <0.001
HIV status
Negative 1.0 Referent
Positive 3.7 1.3–7.9 0.005
Unknown 1.6 0.8–3.3 0.22
Stage at diagnosis
I 1.0 Referent
II 3.5 1.6–8.7 0.003
III 26.7 9.0–78.6 <0.001
Molecular subtypes
Triple negative 1.0 Referent
Luminal A 1.3 0.5–3.4 0.65
Luminal B 1.7 0.9–3.2 0.11
HER2-enriched 3.5 1.2–10.0 0.02
Stage at diagnosis was the strongest predictor of TM.
https://doi.org/10.1371/journal.pone.0182125.t002
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consciously influence that choice, patients with HIV might have preferred TM so as to avoid
having to travel to CMJAH for RT when they were already receiving ART in another clinic or
department.
We had no data about income, but we speculate that patients with HIV may have been
poorer than other patients. Poverty is known to be a strong predictor of HIV status and HIV-
related medical complications. Poorer patients may choose TM because they cannot manage
the additional hospital visits or afford the transportation required to receive adjuvant RT fol-
lowing BCS. [23] Lastly, patients with HIV are more likely to have other medical complica-
tions, such as concurrent infections, and to be taking medications, such as ART, which may
make additional treatment more burdensome. HIV-infected patients may also have been more
likely to be responsible for the care of others, including young children or other family mem-
bers with HIV and/or tuberculosis.
In recent years, TM has regained some popularity in the United States, in part due to the
growing acceptance of prophylactic contralateral TM, increased access to breast reconstruction
surgery, improved cosmetic results of such surgery, and increasing use of breast MRI and
genetic testing[24].
In the United States, patient-related factors associated with the use of TM include older age,
fear of recurrence, perceived survival benefits, previous contralateral TM, medical comorbidi-
ties, insurance coverage, and cultural preferences.[25] In a large SEER-based analysis, factors
correlated with the decision to undergo BCS as opposed to TM included younger patient age,
higher socioeconomic status, favorable tumor characteristics, black race, and urban location.
In another study at a single center in Kentucky, race was not independently associated with
the choice of BCS versus TM.[26]
In select circumstances where risk for local recurrence is considered high, TM may be indi-
cated for patients with localized disease because local recurrence is associated with a higher
risk of death from breast cancer. In the absence of guidelines specifying a risk threshold, a
review article concluded that BCS is permissible if the patient’s estimated risk of local recur-
rence is less than 1% per year, or less than 10% at 10 years. Important risk factors for breast
cancer recurrence are: positive margins, young age, decision not to pursue radiotherapy, and
intrinsic subtype. The review article also recommended exercising extreme caution when
choosing BCS for patients who are younger than 35 years of age; have extensive DCIS (particu-
larly if younger than 40 years of age); have incompletely resected invasive or in situ cancer; or
are ineligible for radiation therapy (RT). Features of the cancer thought to indicate high risk,
but not considered contraindications to BCS, were: multifocality, multicentricity, retroareolar
location, vascular invasion, and lobular histology.[27] Generally, BCS was not recommended if
it could not achieve a good cosmetic outcome or, more importantly, complete tumor excision.
A clear disadvantage of BCS is the higher risk of requiring a second operation, mainly
because of positive margins or those deemed to be unsafe. Twenty-five percent of our BCS
patients with early stage breast cancer underwent a second operation within 6 weeks, most
often a completion TM. This high re-operation and TM rate was largely due to decision mak-
ing in our multidisciplinary meetings, where we had a preference for widely clear margins
above 5mm. Nearly 19% of specimens from our patients who had BCS had 1–5 mm margins
that were in many cases the indication for re-operation. Had we followed current guidelines
[28, 29], our BCS re-operation rate would have been below 15%. Furthermore, close margins
were often unexpected areas of associated DCIS that could not be identified by pre-operative
imaging; mammography is known to underestimate the presence and the extent of DCIS.
Our data show that at least 80% of our referred patients received RT. Although they had to
travel ~18 kilometers from their place of residence for that treatment, they had better access to
RT than patients in most parts of sub-Saharan Africa, where very limited facilities exist.[30]
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Nevertheless, some patients who are eligible for BCS from a surgical perspective may opt for
TM in order to obviate the need for adjuvant RT.
Studies from other countries in sub-Saharn Africa report that many patients, regardless of
age and educational background, refuse TM which may be the only surgical option even
though they understand that they may have cancer and that their condition may otherwise be
lethal. In one study of Nigerian breast cancer patients, 44.7% of patients delayed TM because
of fear.[31] Patients feared disfigurement, effect on relationships with a partner, and surgical
complications leading to extended duration or escalation of care.[32]
Interestingly, among women in Switzerland who were diagnosed with operable breast can-
cers but declined surgery, common reasons included depression, desire to pursue alternative
therapies, medical comorbidities, fear, age, and inadequate insurance.[33]
Our study is one of the first to describe HIV status in relation to surgery for breast cancer
in South Africa. We have studied a population in South Africa with a high prevalence of HIV
infection and with access to ART and standard breast cancer treatments. Limitations include
the relatively small sample size, the lack of data on socioeconomic status, and the lack of fol-
low-up for long-term outcomes, such as survival. In addition, our analysis drew on what was
originally an administrative database; as such it may have been affected by bias or confound-
ing. We have initiated a prospective multi-center collaborative South African outcome study
to address these issues. However, meanwhile our efforts have taught us that an oncoplastic
approach in breast surgery is feasible even in a resource constrained setting, and that zero tol-
erance of long waits for surgery reduces the surgical workload and minimizes loss to
treatment.
Conclusions
Patients with breast cancer in our cohort from South Africa, even those with stage I disease,
were more likely than patients in more affluent countries to have a TM than BCS. Stage at
diagnosis was the strongest determinant of type of surgery, but HIV status also appeared to be
a determinant of surgical procedure (probably by affecting patients rather than doctors’ deci-
sion making). We found also a possible association with HER2 enriched status and presence of
lymphovascular invasion, both indicators of aggressive disease. The reasons for these associa-
tions need to be better understood, as do the reasons for the choice of TM when BCS is a valid
option. Although our relatively low BCS numbers and high re-operation rates reflect the chal-
lenges of offering BCS in a poorly resourced environment, we believe it is worth the effort.
One could argue that we are adding complexity to an already strained health system, but BCS
has the potential to change perceptions and alleviate the fears of surgical mutilation associated
with breast cancer. BCS may be a potential catalyst for women to come forward with earlier
disease.
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